Pleiotropic Effects of an Incretin Hormone.
10.4093/jkd.2013.14.3.120
- Author:
Seungjoon OH
1
Author Information
1. Division of Endocrinology & Metabolism, Department of Internal Medicine, Kyung Hee University School of Medicine, Seoul, Korea. orqwic@chollian.net
- Publication Type:Original Article
- Keywords:
Glucagon-like peptide 1;
Incretins;
Incretin/therapeutic use
- MeSH:
Appetite;
Blood Glucose;
Body Weight;
Central Nervous System;
Enteroendocrine Cells;
Glucagon;
Glucagon-Like Peptide 1;
Incretins;
Insulin;
Insulin-Secreting Cells;
Liver;
Receptors, G-Protein-Coupled;
Stomach
- From:Journal of Korean Diabetes
2013;14(3):120-124
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
The incretin hormones glucagon like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) have recently received much attention for their roles in type 2 diabetes therapy. GLP-1 stimulated insulin secretion in a glucose-dependent manner and is secreted by intestinal L cells. It also regulates blood glucose concentration, stomach motility, appetite, and body weight. These actions are mediated through G-protein-coupled receptors highly expressed on pancreatic beta cells and also exert indirect metabolic actions. Activation of GLP-1 receptors also produces nonglycemic effects in various tissues. The pleiotropic effects of GLP-1 have been recently reported. The mechanisms identified in preclinical studies have potential translational relevance for the treatment of disease. Here, the nonglycemic effects of GLP-1, especially those on the liver, central nervous system, and bone, were reviewed.
